← Leaderboards
David A Boothman
Case Western Reserve University
$11,670,216
Attributed
$12,659,011
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,659,011 · 10
By mechanism
R01$11,048,615 · 8
U01$1,483,192 · 1
P30$127,204 · 1
Top collaborators
- Cristina Maria Furdui2 shared
- Melissa Lambeth Kemp2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDna RepairCancer CellResponseCellsResistanceKillingsIn VivoIonizing RadiationTumorBaseDna DamageMediatingPharmaceutical PreparationsGrantCancer PatientNqo1 GeneBeta-LapachoneCell DeathApoptosisDosePathway InteractionsRepairedBreast
Grant awards (48)
Experimental and Developmental Therapeutics Program$31,801
P30 · FY2022 · CA · contact PI
Experimental and Developmental Therapeutics Program$31,801
P30 · FY2021 · CA · contact PI
Experimental and Developmental Therapeutics Program$31,801
P30 · FY2020 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$373,368
R01 · FY2019 · CA · contact PI
Experimental and Developmental Therapeutics Program$31,801
P30 · FY2019 · CA · contact PI
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments$825,581
U01 · FY2018 · CA
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$360,281
R01 · FY2018 · CA · contact PI
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs$347,128
R01 · FY2018 · CA · contact PI
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments$657,611
U01 · FY2017 · CA
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$388,637
R01 · FY2017 · CA · contact PI
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$314,880
R01 · FY2017 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$238,228
R01 · FY2017 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$96,912
R01 · FY2017 · CA · contact PI
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$55,695
R01 · FY2017 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$22,217
R01 · FY2017 · CA · contact PI
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$369,527
R01 · FY2016 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$335,140
R01 · FY2016 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$335,140
R01 · FY2015 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$325,086
R01 · FY2014 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$310,426
R01 · FY2014 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$93,209
R01 · FY2014 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$335,140
R01 · FY2013 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$300,826
R01 · FY2013 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$74,450
R01 · FY2013 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$330,925
R01 · FY2012 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$319,692
R01 · FY2012 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$330,925
R01 · FY2011 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$319,021
R01 · FY2011 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$341,159
R01 · FY2010 · CA · contact PI
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining$328,888
R01 · FY2010 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$341,159
R01 · FY2009 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$175,840
R01 · FY2009 · CA · contact PI
Use of Beta-lapachone for Lung Cancer Chemotherapy$341,159
R01 · FY2008 · CA · contact PI
Use of Beta-Lapachone for Lung Cancer Chemotherapy$331,223
R01 · FY2007 · CA · contact PI
Use of Beta-Lapachone for Lung Cancer Chemotherapy$78,500
R01 · FY2007 · CA · contact PI
Use of Beta-Lapachone for Lung Cancer Chemotherapy$26,169
R01 · FY2007 · CA · contact PI
Use of Beta-Lapachone for Lung Cancer Chemotherapy$341,115
R01 · FY2006 · CA · contact PI
Use of Beta-Lapachone for Lung Cancer Chemotherapy$339,065
R01 · FY2005 · CA
Use of Beta-Lapachone for Lung Cancer Chemotherapy$311,651
R01 · FY2004 · CA
Use of Beta-Lapachone for Lung Cancer Chemotherapy$324,901
R01 · FY2003 · CA
Exploiting IR inducible NQ01 Levels Using Beta Lapachone$246,919
R01 · FY2003 · CA
Exploiting IR inducible NQ01 Levels Using Beta Lapachone$246,919
R01 · FY2002 · CA
DNA MISMATCH REPAIR IN FDURD INDUCED CYTOTOXICITY$211,905
R01 · FY2002 · CA
Exploiting IR inducible NQ01 Levels Using Beta Lapachone$246,919
R01 · FY2001 · CA
XIP8, AN X RAY INDUCIBLE KU70 BINDING PROTEIN$219,596
R01 · FY2001 · CA
DNA MISMATCH REPAIR IN FDURD INDUCED CYTOTOXICITY$205,734
R01 · FY2001 · CA
XIP8, AN X RAY INDUCIBLE KU70 BINDING PROTEIN$213,201
R01 · FY2000 · CA
DNA MISMATCH REPAIR IN FDURD INDUCED CYTOTOXICITY$199,740
R01 · FY2000 · CA